Gaithersburg, Maryland - 4 February 2021: MaxCyte (LSE: MXCT, MXCL), the global cell-based medicines and life sciences company, announces that further to the announcement of a £40 million (approx. $55 million) Subscription via a private placement of 5,740,000 new shares of common stock (the Subscription Announcement ) on 3 February, 2021, Doug Doerfler, Chief Executive Officer and a Founder of the Company, Ron Holtz, Senior Vice President and Chief Accounting Officer and J. Stark Thompson, Non-Executive Chairman, have exercised options in the amount of 755,000 shares of common stock, $0.01 par, of the Company ( Common Stock ) ( Exercise ) in aggregate. The 755,000 new shares of Common Stock issued pursuant to the Exercise ( New Options Common Stock ) have been sold by Doug Doerfler, Ron Holtz and J. Stark Thompson at a price of 700 pence per Common Stock ( Sale ).
About MaxCyte
MaxCyte is a world-leading provider of cell-engineering enabling technology and is responsible for helping to bring next-generation cell and gene-editing therapies to life. The Company s technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 140 cell therapy programmes, with more than 100 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.